JP2007508527A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508527A5
JP2007508527A5 JP2006530040A JP2006530040A JP2007508527A5 JP 2007508527 A5 JP2007508527 A5 JP 2007508527A5 JP 2006530040 A JP2006530040 A JP 2006530040A JP 2006530040 A JP2006530040 A JP 2006530040A JP 2007508527 A5 JP2007508527 A5 JP 2007508527A5
Authority
JP
Japan
Prior art keywords
organ damage
end organ
marker
level
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006530040A
Other languages
English (en)
Japanese (ja)
Other versions
JP4840744B2 (ja
JP2007508527A (ja
Filing date
Publication date
Priority claimed from EP03078161A external-priority patent/EP1522857A1/en
Application filed filed Critical
Publication of JP2007508527A publication Critical patent/JP2007508527A/ja
Publication of JP2007508527A5 publication Critical patent/JP2007508527A5/ja
Application granted granted Critical
Publication of JP4840744B2 publication Critical patent/JP4840744B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006530040A 2003-10-09 2004-09-27 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法 Expired - Fee Related JP4840744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP03078161.1 2003-10-09
PCT/EP2004/010879 WO2005040817A1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010167334A Division JP2010279378A (ja) 2003-10-09 2010-07-26 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2011088342A Division JP5580774B2 (ja) 2003-10-09 2011-04-12 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法

Publications (3)

Publication Number Publication Date
JP2007508527A JP2007508527A (ja) 2007-04-05
JP2007508527A5 true JP2007508527A5 (enExample) 2007-08-02
JP4840744B2 JP4840744B2 (ja) 2011-12-21

Family

ID=34306912

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006530040A Expired - Fee Related JP4840744B2 (ja) 2003-10-09 2004-09-27 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2010167334A Withdrawn JP2010279378A (ja) 2003-10-09 2010-07-26 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2011088342A Expired - Lifetime JP5580774B2 (ja) 2003-10-09 2011-04-12 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2014021394A Expired - Lifetime JP5789009B2 (ja) 2003-10-09 2014-02-06 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2015081540A Pending JP2015171365A (ja) 2003-10-09 2015-04-13 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010167334A Withdrawn JP2010279378A (ja) 2003-10-09 2010-07-26 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2011088342A Expired - Lifetime JP5580774B2 (ja) 2003-10-09 2011-04-12 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2014021394A Expired - Lifetime JP5789009B2 (ja) 2003-10-09 2014-02-06 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
JP2015081540A Pending JP2015171365A (ja) 2003-10-09 2015-04-13 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法

Country Status (14)

Country Link
US (5) US7888137B2 (enExample)
EP (4) EP1522857A1 (enExample)
JP (5) JP4840744B2 (enExample)
CN (2) CN1879022B (enExample)
AT (1) ATE532073T1 (enExample)
AU (2) AU2004284496C1 (enExample)
CA (2) CA2542033C (enExample)
CY (2) CY1112359T1 (enExample)
DK (2) DK2317324T3 (enExample)
ES (2) ES2530567T3 (enExample)
PL (2) PL1682907T3 (enExample)
PT (2) PT2317324E (enExample)
SI (2) SI1682907T1 (enExample)
WO (1) WO2005040817A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
AU2007301981A1 (en) * 2006-09-25 2008-04-03 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
US20100055723A1 (en) * 2007-01-23 2010-03-04 University Of Virginia Patent Foundation Galectin-3-Binding Protein as a Biomarker of Cardiovascular Disease
AU2008302489A1 (en) * 2007-09-17 2009-03-26 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
CN102576028A (zh) * 2009-08-25 2012-07-11 保函医药公司 半乳凝集素-3和心脏再同步疗法
JP2013536408A (ja) * 2010-07-02 2013-09-19 ビージー メディシン， インコーポレイテッド ガレクチン−３測定によりモニタリングされるスタチン療法
EP2631656B1 (en) * 2010-10-18 2016-07-27 Hideaki Hara Marker for amyotrophic lateral sclerosis, and use thereof
EP2460890A1 (en) 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
CA2825954A1 (en) * 2011-01-31 2012-08-09 Bg Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
ES2669068T3 (es) * 2011-12-08 2018-05-23 Eliaz Therapeutics, Inc Reducción de niveles de galectina-3 mediante plasmaféresis
ES2742291T3 (es) * 2012-09-27 2020-02-13 Siemens Healthcare Diagnostics Inc Cistatina C y Galectina-3 como biomarcadores para la hipertensión arterial pulmonar
EP2919802A4 (en) * 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
WO2016113720A1 (en) 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
JP6612864B2 (ja) * 2015-05-28 2019-11-27 京セラ株式会社 切削工具
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用
CN118524852A (zh) * 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US6319676B1 (en) 1995-05-02 2001-11-20 Carter Wallace, Inc. Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
JP5264026B2 (ja) 1997-06-10 2013-08-14 エルパス・インコーポレイテッド 心疾患の早期発見のための方法
DK1018018T3 (da) * 1997-09-05 2010-11-15 Southern Medical Diagnostics Pty Fremgangsmåde til diagnosticering
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
ES2244052T5 (es) * 1997-10-24 2011-03-28 SHIONOGI & CO., LTD. Procedimiento de inhibición de la descomposición de péptidos natriuréticos y procedimento mejorado de dosificado de péptidos natriuréticos con la ayuda de los indicados péptidos.
JP5030329B2 (ja) * 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置
PL204235B1 (pl) * 1999-01-29 2009-12-31 Roche Diagnostics Gmbh Sposób wykrywania natywnego N-końcowego proBNP, zastosowanie tego sposobu, zastosowanie zrekombinowanego N-końcowego proBNP, przeciwciała przeciw zrekombinowanemu N-końcowemu proBNP, linie komórkowe i sposoby wytwarzania przeciwciał poliklonalnych i monoklonalnych
DE60031512T2 (de) * 1999-02-19 2007-08-23 University Of Iowa Research Foundation Diagnostika und therapeutika für maculare degeneration
WO2001014581A2 (en) * 1999-08-20 2001-03-01 Board Of Regents, The University Of Texas System Hdac4 and hdac5 in the regulation of cardiac gene expression
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
AU2001251351A1 (en) 2000-04-05 2001-10-23 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
KR100395254B1 (ko) 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
AU2002218026A1 (en) * 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US20030166017A1 (en) * 2000-11-09 2003-09-04 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
EP1385993B8 (en) * 2000-12-08 2011-09-21 Celldex Therapeutics, Inc. Method of detecting and treating tuberous sclerosis complex associated disorders
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
US7041449B2 (en) 2001-03-19 2006-05-09 Wisconsin Alumni Research Foundation Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice
US20060019235A1 (en) 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
ATE405670T1 (de) * 2002-05-13 2008-09-15 Arexis Ab Autoimmunerkrankungen und nadph-oxidase-defekte
AU2003290537A1 (en) 2002-10-24 2004-05-13 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2004111654A2 (en) 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
EP1846576A4 (en) 2005-02-01 2009-01-07 Us Gov Health & Human Serv BIOMARKERS OF TISSUE STATUS
WO2006102497A2 (en) 2005-03-22 2006-09-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
AU2009340423B2 (en) 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
CN102576028A (zh) 2009-08-25 2012-07-11 保函医药公司 半乳凝集素-3和心脏再同步疗法

Similar Documents

Publication Publication Date Title
JP2007508527A5 (enExample)
US10132809B2 (en) Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
JP6941324B2 (ja) 新規な肝硬変または肝線維症のマーカー
WO2007011412A3 (en) Diagnosis and prognosis of infectious diesease clinical phenotypes and other physiologic states using host gene expresion biomarkers in blood
JP2011177182A5 (enExample)
DE60207979D1 (de) Verfahren und Vorrichtung zur Bestimmung der Gewebespezifität von freier DNA in Körperflüssigkeiten
EP1849002A4 (en) Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
JP2010506147A5 (enExample)
RU2009139295A (ru) Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек
EP2339348A3 (en) Method for diagnosing neuro-degenerative disease
EP1838867A4 (en) APOLIPOPROTEIN A II ISOFORM AS A BIOMARKER FOR PROSTATE CANCER
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
ATE531820T1 (de) Gesundheitszustandstest
JP2009524829A5 (enExample)
ATE447715T1 (de) Automatische glykofingerabdruck-strategie
JP2009515556A5 (enExample)
JP2009511905A5 (enExample)
RU2008103988A (ru) Способ диагностики рассеяного склероза
JP2010538252A5 (enExample)
JP2006508326A5 (enExample)
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
JP2008547006A5 (enExample)
JP2007536913A5 (enExample)
DK1853735T3 (da) Fremgangsmåder til detektering af progressionen af cervikal dysplasi i let grad